NPC1 as a Modulator of Disease Severity and Viral Entry of SARSCoV- 2

Author(s): Cecilia Vial, Juan Francisco Calderón, Andrés D. Klein*

Journal Name: Current Molecular Medicine

Volume 21 , Issue 1 , 2021

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


The COVID-19 plague is hitting mankind. Several viruses, including SARS-CoV-1, MERS-CoV, EBOV, and SARS-CoV-2, use the endocytic machinery to enter the cell. Genomic variants in NPC1, which encodes for the endo-lysosomal Niemann-Pick type C1 protein, restricts the host-range of viruses in bats and susceptibility to infections in humans. Lack of NPC1 and its pharmacological suppression inhibits many viral infections including SARS-CoV-1 and Type I Feline Coronavirus Infection. Antiviral effects of NPC1-inhibiting drugs for COVID-19 treatment should be explored.

Keywords: COVID-19, SARS-Cov-2, Niemann-Pick C1, modifier gene, drug repurposing, virus, infection.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 13 July, 2020
Page: [2 - 4]
Pages: 3
DOI: 10.2174/1566524020666200713175426
Price: $65

Article Metrics

PDF: 38